Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Talaris Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio"
10/06/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Investor Contact"
04/14/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
10/20/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
Docs: "Three months ended June 30, 2022 2021 Operating expenses Research and development $ 13,187 $ 7,570 General and administrative $ 5,228 $ 3,487 Total operating expenses 18,415 11,057 Loss from operations Interest and other income , net $ 319 $ Net loss attributable to common stockholders $ $ Net loss per common share, basic and diluted $ $ Weighted average number of common shares outstanding used in computation of net loss per common share, basic and diluted $ 41,088,085 $ 27,373,165 Balance Sheets Selected Financial Data June 30, December 31, 2022 2021 Cash, cash equivalents and marketable securities $ 207,112 $ 243,971 Working capital 204,706 238,527 Total assets 220,916 251,422 Other liabilities 2,822 626 Total liabilities 10,174 8,613 Total convertible preferred stock and stockholders’ ..."
06/30/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update Provided initial clinical update from its Phase 3 clinical trial evaluating FCR001 in living donor kidney transplant patients"
11/04/2021 8-K Other Events  Interactive Data
11/02/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction"
08/12/2021 8-K Quarterly results
06/14/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy